Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant Tumors

Summary

The trial was divided into two phases: dose escalation and dose expansion. The dosing regimens were single-dose study and continuous dosing study. A single-center, open, non-randomized, single-arm clinical trial design was adopted. Subjects with advanced malignant tumors were selected to take TQB3205 capsules orally to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TQB3205 capsules.

Timeline

Start

2026-04-15

Primary completion

2027-12

Completion

2028-12

Drugs

Indications